Can Betatrophin be a New Biochemical Marker in the Diagnosis of Insulinoma?

Suleyman Aydin
2017 Journal of Clinical and Molecular Endocrinology  
Originating from the β cells of Langerhans islets, insulinoma has an incidence of 1 to 4 in one million in the general population, but is the most common tumor among pancreatic neuroendocrine tumors [1] . It can be life-threatening depending on the presence of hypoglycemia. It is diagnosed through clinical [anxiety, nervousness, tremor, sweating, feeling of hunger, palpitation, restlessness, angina, and especially the presence of the Whipple triad (hypoglycemia symptoms + low blood sugar + the
more » ... isappearance of symptoms upon glucose intake)] and laboratory findings. Radiological imaging is helpful in distinctive diagnosis and determination of the operation procedure. Insulinoma diagnosis is supported by C peptide >0.6 ng/ml, insulin >3 µIU/mL, proinsulin >5 pmol/L, simultaneously with hypoglycemia (plasma glucose <55 mg/dl) [1,2]. Editorial iMedPub Journals
doi:10.21767/2572-5432.100040 fatcat:5y4tbcbavfc4vndxkbfupruei4